NHS England has been asked to provide an interim report to the Secretary of State for Health and Social Care by the end of May 2019. The review will be clinically led by the NHS England and NHS Improvement Medical Director and Chief Pharmaceutical Officer, drawing on further specialist support as required.<\/p>
NHS England will work with patient groups and the All Party Parliamentary Group on Medical Cannabis under Prescription to identify a sample of patients that have been seeking to access cannabis-based products for medicinal use through the National Health Service. Case reviews will involve interviews with relevant individuals who are involved in the decision to prescribe cannabis-based products for medicinal use, including patients, carers and relevant trust staff.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-08", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "248611"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-08T13:57:42.103Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-04-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what the timeframe is for the process evaluation being undertaken by the NHS on prescribing cannabis-based products for medical use; and if he will he make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1528", "label" : {"_value" : "Biography information for Sir Mike Penning"} } , "tablingMemberConstituency" : {"_value" : "Hemel Hempstead"} , "tablingMemberPrinted" : [{"_value" : "Sir Mike Penning"} ], "uin" : "248610"} , {"_about" : "http://data.parliament.uk/resources/1123520", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1123520/answer", "answerText" : {"_value" : "
NHS England has been asked to provide an interim report to the Secretary of State for Health and Social Care by the end of May 2019. The review will be clinically led by the NHS England and NHS Improvement Medical Director and Chief Pharmaceutical Officer, drawing on further specialist support as required.<\/p>
NHS England will work with patient groups and the All Party Parliamentary Group on Medical Cannabis under Prescription to identify a sample of patients that have been seeking to access cannabis-based products for medicinal use through the National Health Service. Case reviews will involve interviews with relevant individuals who are involved in the decision to prescribe cannabis-based products for medicinal use, including patients, carers and relevant trust staff.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-08", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "248610"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-08T13:57:42.167Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-04-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, who he will be engaging with in the process evaluation on prescribing cannabis-based products for medical use.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1528", "label" : {"_value" : "Biography information for Sir Mike Penning"} } , "tablingMemberConstituency" : {"_value" : "Hemel Hempstead"} , "tablingMemberPrinted" : [{"_value" : "Sir Mike Penning"} ], "uin" : "248611"} , {"_about" : "http://data.parliament.uk/resources/1123521", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1123521/answer", "answerText" : {"_value" : "
To stimulate research proposals, the National Institute for Health Research (NIHR) has issued two calls for research into cannabis-based products for medicinal use and has taken steps to advertise the call to all manufacturers interested in supplying the United Kingdom market.<\/p>
The NIHR also remain open to the submission of proposals outside of these specific calls. Proposals made to NIHR are assessed for scientific rigour, which will include the design of the trials, before funding is allocated to the applicants.<\/p>
The process for selecting people for inclusion in any trials will be determined by the researchers and will be dependent on the study design used in the trial.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-08", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-08T13:59:06.047Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-04-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, how the National Institute for Health Research will identify patients with severe intractable epilepsy to use as a placebo in research into the safety and clinical efficacy and effectiveness of cannabis-based products for medical use in humans.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1528", "label" : {"_value" : "Biography information for Sir Mike Penning"} } , "tablingMemberConstituency" : {"_value" : "Hemel Hempstead"} , "tablingMemberPrinted" : [{"_value" : "Sir Mike Penning"} ], "uin" : "248612"} , {"_about" : "http://data.parliament.uk/resources/1123527", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1123527/answer", "answerText" : {"_value" : "
The NHS Long Term Plan included an ambition that 75% of cancers will be diagnosed at stage 1 and 2 by 2028. The plan sets out a number of key steps to achieve this, including raising greater awareness of symptoms of cancer, accelerating access to diagnosis and treatment and maximising the number of cancers that we identify through screening. Meeting this ambition will also require the National Health Service to harness new technological advances to target at risk patients more effectively; directing our research and innovation effort to the areas where the data tells us we can have the biggest impact; and mobilising the NHS so that we can adopt proven new approaches more quickly.<\/p>
In February 2019, NHS England announced that Targeted Lung Health Checks will be one of the first projects to roll out following the launch of the NHS Long Term Plan that was published in January 2019. The Targeted Lung Health Check programme will cover 10 initial sites covering 14 clinical commissioning groups until 2023 in areas that have been selected as they have some of the highest rates of lung cancer mortality. People aged 55-74 that have ever smoked will be invited to have a free lung check. Results from these initial sites will form the basis for a wider rollout across the country.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-02", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-02T15:53:55.987Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-04-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Lung Cancer: Diagnosis"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase the number of diagnoses of lung cancer before it has reached stage 3 or 4.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/308", "label" : {"_value" : "Biography information for Mr Jim Cunningham"} } , "tablingMemberConstituency" : {"_value" : "Coventry South"} , "tablingMemberPrinted" : [{"_value" : "Mr Jim Cunningham"} ], "uin" : "248575"} , {"_about" : "http://data.parliament.uk/resources/1123528", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1123528/answer", "answerText" : {"_value" : "
Public Health England (PHE) continues to run awareness campaigns focused on the symptoms of lung cancer where the messaging is relevant to both smokers and non-smokers.<\/p>
For example, the PHE Be Clear on Cancer Respiratory Symptoms campaign encourages those with a persistent cough or inappropriate breathlessness to visit their doctor, with the aim of improving earlier diagnosis of heart and lung disease, including lung cancer. The campaign has run twice nationally, in 2016 and 2017. This campaign can be viewed at the following link:<\/p>